Literature DB >> 23677957

Application of the fecal microRNA test to the residuum from the fecal occult blood test.

Nobuyoshi Yamazaki1, Yoshikatsu Koga, Seiichiro Yamamoto, Yasuo Kakugawa, Yosuke Otake, Ryuichi Hayashi, Norio Saito, Yasuhiro Matsumura.   

Abstract

OBJECTIVE: Though the fecal occult blood test is used for colorectal cancer screening worldwide, it does not have a particularly high sensitivity for detecting colorectal cancer. Here we investigated the applicability of the fecal microRNA test to fecal samples that had been used for a previous fecal occult blood test and stored under various conditions.
METHODS: Five colorectal cancer patients and five healthy volunteers were enrolled. Fecal samples were stored for 0-5 days at 4°C, room temperature or 37°C. Total RNA was extracted from the fecal occult blood test residuum and microRNA expression was analyzed by real-time reverse transcription polymerase chain reaction.
RESULTS: There were no remarkable differences either in colorectal cancer patients or in controls with regard to the concentration of RNA extracted from the fecal occult blood test residuum in any of the storage groups compared with the samples prepared on day 0 (Group 0). Ribosomal RNA stored at room temperature or 37°C degraded rapidly. In contrast, the ribosomal RNA stored at 4°C remained intact for at least 5 days. The microRNAs in samples stored at 4°C and room temperature were conserved; however, the microRNAs stored at 37°C were significantly degraded compared with Group 0 (P < 0.05). In the residuum stored at 4°C up to 5 days, the relative quantification of miR-106a normalized with miR-24 in colorectal cancer patients was significantly higher than those in healthy volunteers (P < 0.05). In contrast, the quantification of normalized miR-106a was remarkably low in samples stored at room temperature and 37°C.
CONCLUSIONS: Fecal microRNA of sufficient quality for reverse transcription polymerase chain reaction analysis was extracted from the fecal occult blood test residuum stored at 4°C for up to 5 days.

Entities:  

Keywords:  cancer screening; colorectal cancer; fecal miRNA; fecal occult blood test

Mesh:

Substances:

Year:  2013        PMID: 23677957     DOI: 10.1093/jjco/hyt068

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  9 in total

Review 1.  MicroRNAs in colorectal cancer as markers and targets: Recent advances.

Authors:  Jing-Jia Ye; Jiang Cao
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

2.  Fecal microRNA profile in patients with colorectal carcinoma before and after curative surgery.

Authors:  M T Rotelli; M Di Lena; A Cavallini; C Lippolis; L Bonfrate; N Chetta; P Portincasa; D F Altomare
Journal:  Int J Colorectal Dis       Date:  2015-05-20       Impact factor: 2.571

Review 3.  MicroRNAs potential utility in colon cancer: Early detection, prognosis, and chemosensitivity.

Authors:  Michael Hollis; Kavitha Nair; Arpita Vyas; Lakshmi Shankar Chaturvedi; Sahil Gambhir; Dinesh Vyas
Journal:  World J Gastroenterol       Date:  2015-07-21       Impact factor: 5.742

4.  Early second-trimester serum microRNAs as potential biomarker for nondiabetic macrosomia.

Authors:  Lingmin Hu; Jing Han; Fangxiu Zheng; Hongxia Ma; Jiaping Chen; Yue Jiang; Hua Jiang
Journal:  Biomed Res Int       Date:  2014-10-27       Impact factor: 3.411

5.  MicroRNA-20a in human faeces as a non-invasive biomarker for colorectal cancer.

Authors:  Tung On Yau; Chung Wah Wu; Ceen-Ming Tang; Yingxuan Chen; Jingyuan Fang; Yujuan Dong; Qiaoyi Liang; Simon Siu Man Ng; Francis Ka Leung Chan; Joseph Jao Yiu Sung; Jun Yu
Journal:  Oncotarget       Date:  2016-01-12

6.  High expression of miR-181c as a predictive marker of recurrence in stage II colorectal cancer.

Authors:  Nobuyoshi Yamazaki; Yoshikatsu Koga; Hirokazu Taniguchi; Motohiro Kojima; Yukihide Kanemitsu; Norio Saito; Yasuhiro Matsumura
Journal:  Oncotarget       Date:  2017-01-24

Review 7.  Function and mechanisms of microRNA-20a in colorectal cancer.

Authors:  Zheng Xiao; Shi Chen; Shujun Feng; Yukun Li; Juan Zou; Hui Ling; Ying Zeng; Xi Zeng
Journal:  Exp Ther Med       Date:  2020-01-08       Impact factor: 2.447

Review 8.  Fecal microRNAs, Fecal microRNA Panels, or Combinations of Fecal microRNAs with Fecal Hemoglobin for Early Detection of Colorectal Cancer and Its Precursors: A Systematic Review.

Authors:  Zitong Zhao; Anna Zhu; Megha Bhardwaj; Petra Schrotz-King; Hermann Brenner
Journal:  Cancers (Basel)       Date:  2021-12-23       Impact factor: 6.639

9.  MicroRNA-223 and microRNA-92a in stool and plasma samples act as complementary biomarkers to increase colorectal cancer detection.

Authors:  Pi-Yueh Chang; Chia-Chun Chen; Yu-Sun Chang; Wen-Sy Tsai; Jeng-Fu You; Geng-Ping Lin; Ting-Wen Chen; Jinn-Shiun Chen; Err-Cheng Chan
Journal:  Oncotarget       Date:  2016-03-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.